PortfoliosLab logoPortfoliosLab logo
BDTX vs. STTK
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

BDTX vs. STTK - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Black Diamond Therapeutics, Inc. (BDTX) and Shattuck Labs, Inc. (STTK). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, BDTX achieves a -13.58% return, which is significantly lower than STTK's 30.14% return.


BDTX

1D
-3.67%
1M
-22.22%
YTD
-13.58%
6M
-21.93%
1Y
-16.00%
3Y*
-3.54%
5Y*
-30.24%
10Y*

STTK

1D
-2.46%
1M
-31.36%
YTD
30.14%
6M
82.69%
1Y
365.69%
3Y*
18.84%
5Y*
-30.36%
10Y*
*Multi-year figures are annualized to reflect compound growth (CAGR)

BDTX vs. STTK - Yearly Performance Comparison


2026 (YTD)202520242023202220212020
BDTX
Black Diamond Therapeutics, Inc.
-13.58%13.55%-23.84%56.11%-66.23%-83.37%-5.12%
STTK
Shattuck Labs, Inc.
30.14%201.65%-83.03%210.00%-72.97%-83.76%170.85%

Correlation

The correlation between BDTX and STTK is 0.27, which is low. Their price movements are largely independent, making them effective diversification partners.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.27

Correlation (3Y)
Calculated over the trailing 3-year period

0.24

Correlation (5Y)
Calculated over the trailing 5-year period

0.26

Correlation (All Time)
Calculated using the full available price history since Oct 12, 2020

0.25

Fundamentals

Market Cap

BDTX:

$120.19M

STTK:

$533.11M

EPS

BDTX:

-$0.76

STTK:

-$0.59

PB Ratio

BDTX:

1.15

STTK:

5.56

Total Revenue (TTM)

BDTX:

$0.00

STTK:

$1.00M

Gross Profit (TTM)

BDTX:

-$152.00K

STTK:

-$835.00K

EBITDA (TTM)

BDTX:

-$40.34M

STTK:

-$48.60M

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

BDTX vs. STTK — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

BDTX
BDTX Risk / Return Rank: 3535
Overall Rank
BDTX Sharpe Ratio Rank: 3333
Sharpe Ratio Rank
BDTX Sortino Ratio Rank: 3737
Sortino Ratio Rank
BDTX Omega Ratio Rank: 3838
Omega Ratio Rank
BDTX Calmar Ratio Rank: 3232
Calmar Ratio Rank
BDTX Martin Ratio Rank: 3333
Martin Ratio Rank

STTK
STTK Risk / Return Rank: 9494
Overall Rank
STTK Sharpe Ratio Rank: 9797
Sharpe Ratio Rank
STTK Sortino Ratio Rank: 9393
Sortino Ratio Rank
STTK Omega Ratio Rank: 9191
Omega Ratio Rank
STTK Calmar Ratio Rank: 9797
Calmar Ratio Rank
STTK Martin Ratio Rank: 9595
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

BDTX vs. STTK - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Black Diamond Therapeutics, Inc. (BDTX) and Shattuck Labs, Inc. (STTK). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


BDTXSTTKDifference
Sharpe ratioReturn per unit of total volatility

-3.86

Sortino ratioReturn per unit of downside risk

-3.40

Omega ratioGain probability vs. loss probability

1.04

1.45

-0.41

Calmar ratioReturn relative to maximum drawdown

-0.28

9.28

-9.55

Martin ratioReturn relative to average drawdown

-0.46

19.92

-20.38

BDTX vs. STTK - Sharpe Ratio Comparison

The current BDTX Sharpe Ratio is -0.19, which is lower than the STTK Sharpe Ratio of 3.67. The chart below compares the historical Sharpe Ratios of BDTX and STTK, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Sharpe Ratios by Period


BDTXSTTKDifference

Sharpe Ratio (1Y)

Calculated over the trailing 1-year period

-0.19

3.67

-3.86

Sharpe Ratio (5Y)

Calculated over the trailing 5-year period

-0.23

-0.26

+0.03

Sharpe Ratio (All Time)

Calculated using the full available price history

-0.30

-0.19

-0.11

Drawdowns

BDTX vs. STTK - Drawdown Comparison

The maximum BDTX drawdown since its inception was -97.21%, roughly equal to the maximum STTK drawdown of -98.73%. Use the drawdown chart below to compare losses from any high point for BDTX and STTK.


Loading charts...

Drawdown Indicators


BDTXSTTKDifference

Max Drawdown

Largest peak-to-trough decline

-97.21%

-98.73%

+1.52%

Max Drawdown (1Y)

Largest decline over 1 year

-58.32%

-39.72%

-18.60%

Max Drawdown (3Y)

Largest decline over 3 years

-83.09%

-93.45%

+10.36%

Max Drawdown (5Y)

Largest decline over 5 years

-90.50%

-97.59%

+7.09%

Current Drawdown

Current decline from peak

-95.31%

-91.75%

-3.56%

Average Drawdown

Average peak-to-trough decline

-78.59%

-83.06%

+4.47%

Ulcer Index

Depth and duration of drawdowns from previous peaks

34.94%

18.46%

+16.48%

Volatility

BDTX vs. STTK - Volatility Comparison

Black Diamond Therapeutics, Inc. (BDTX) has a higher volatility of 53.78% compared to Shattuck Labs, Inc. (STTK) at 23.12%. This indicates that BDTX's price experiences larger fluctuations and is considered to be riskier than STTK based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


BDTXSTTKDifference

Volatility (1M)

Calculated over the trailing 1-month period

53.78%

23.12%

+30.66%

Volatility (6M)

Calculated over the trailing 6-month period

72.08%

51.52%

+20.56%

Volatility (1Y)

Calculated over the trailing 1-year period

83.87%

100.61%

-16.74%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

132.74%

117.35%

+15.39%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

124.05%

114.28%

+9.77%

Dividends

BDTX vs. STTK - Dividend Comparison

Neither BDTX nor STTK has paid dividends to shareholders.


Tickers have no history of dividend payments

Financials

BDTX vs. STTK - Financials Comparison

This section allows you to compare key financial metrics between Black Diamond Therapeutics, Inc. and Shattuck Labs, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.0020.00M40.00M60.00M2022202320242025202600
(BDTX) Total Revenue
(STTK) Total Revenue
Values in USD except per share items

Frequently Asked Questions


BDTX and STTK have a correlation of 0.27, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

BDTX has higher volatility (53.78%) compared to STTK (23.12%). In terms of maximum drawdown, BDTX dropped -97.21% vs STTK's -98.73%.

STTK currently has the higher Sharpe Ratio (3.67 vs -0.19), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for BDTX and STTK

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer